Community-Acquired Pneumonia for the Hospitalist: Updates and Controversies

Area of Science:

• Pulmonology
• Infectious Diseases
• Clinical Practice Guidelines

Background:

• The 2019 American Thoracic Society (ATS)/Infectious Disease Society of America (IDSA) guidelines for community-acquired pneumonia (CAP) marked significant updates.
• Key changes included the discontinuation of the term "healthcare-associated pneumonia" (HCAP).
• Specific recommendations addressed procalcitonin use, corticosteroid administration, and microbial testing for resistant pathogens.

Purpose of the Study:

• To review and synthesize research published after the 2019 ATS/IDSA guidelines.
• To address remaining questions and provide clarity on areas of uncertainty in CAP diagnosis and treatment.
• To offer an updated perspective on best practices for managing community-acquired pneumonia.

Main Methods:

• Literature review of studies published post-2019 ATS/IDSA guidelines.
• Analysis of research addressing specific guideline recommendations and ambiguities.
• Synthesis of findings to inform current clinical practice.

Main Results:

• Recent studies offer insights into the utility of procalcitonin and corticosteroids in CAP management.
• Evidence continues to evolve regarding optimal diagnostic strategies, including microbial cultures for specific patient groups.
• The abandonment of the HCAP category necessitates careful consideration of patient risk factors.

Conclusions:

• Ongoing research is refining the application of the 2019 ATS/IDSA CAP guidelines.
• Clinical decision-making requires integrating new evidence with established recommendations.
• Further studies are needed to fully resolve remaining uncertainties in community-acquired pneumonia treatment.